PD-(L)1 blockade has made inroads into triple-negative breast cancer, but ER+/Her2- space is still a no go, judging by $MRK flop in Keynote-B49. From #Esmo26 via @ApexOnco -> ht

Jacob Plieth· @JacobPlieth · X·2026-10-24 15:16· 23 hours agoScore70

Body · original

PD-(L)1 blockade has made inroads into triple-negative breast cancer, but ER+/Her2- space is still a no go, judging by $MRK flop in Keynote-B49. From #Esmo26 via @ApexOnco -> https://www.apexonco.com/esmo-2026-keytrudas-breast-cancer-flop

520 views · 2 likes · 0 reposts · 0 replies

Conference abstracts

LBA51matched by Proffered paper 2: Breast cancer, early and advanced stage

Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)

https://esmocongress.esmo.org

Source: Jacob Plieth · x.com